Pfizer kidney cancer drug gets EU approval

(Reuters) - Pfizer Inc said its oral drug Inlyta received European approval as a second-line treatment for kidney cancer patients who do not respond to an initial chemotherapy.

via Reuters: Health News Read More Here..